PMID: 8609155Jan 1, 1996Paper

Modulation of multidrug resistance by BIBW22BS in blasts of de novo or relapsed or persistent acute myeloid leukemia ex vivo

Journal of Cancer Research and Clinical Oncology
J K SchröderM E Scheulen

Abstract

The phenylpteridine derivative BIBW22BS (BIBW22) is a potent modulator of multidrug resistance (MDR). We investigated BIBW22 in comparison to dexniguldipine and verapamil as modifier of MDR in blasts of de novo, relapsed or persistent acute myeloid leukemia (AML) in vitro. All patients with relapsed or persistent AML had been pretreated with idarubicin and cytosine arabinoside. The degree of MDR was determined by efflux kinetics of rhodamine 123 (R123), daunorubicin, and idarubicin measured by flow cytometry (FACS). A total of 51 patients with AML, 25 de novo and 26 relapsed or persistent, were investigated. While only 6 out of 25 de novo AML blast populations showed moderate efflux of R123 and daunorubicin, 17 out of 26 blast populations of relapsed or persistent AML had an efflux between 20% and 44% within 15 min ex vivo. This efflux could be significantly inhibited by 1 microM BIBW22, 1 microM dexniguldipine, or 10 microM verapamil. For idarubicin we found an effusion of 40+/-9% within 15 min in all blast populations that could not be inhibited by the modulators. Clinically achievable drug concentrations causing only moderate side-effects are in the range of 0.5 microM dexniguldipine and 3 microM verapamil. Up to now, BIBW22...Continue Reading

References

Oct 1, 1992·British Journal of Haematology·C SelleriB Rotoli
Jul 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W R VoglerP L Banks
Dec 1, 1990·Cancer Treatment Reviews·S B Kaye
May 15, 1991·Journal of the National Cancer Institute·M R Baer, C D Bloomfield
May 15, 1991·Journal of the National Cancer Institute·R PirkerL Havelec
May 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonM J Keating
Jan 1, 1990·Leukemia Research·H SatoH D Preisler
Aug 3, 1988·Biochimica Et Biophysica Acta·G BradleyV Ling
Nov 1, 1986·Fundamental and Applied Toxicology : Official Journal of the Society of Toxicology·J M MansonJ San Sebastian
Mar 1, 1985·Somatic Cell and Molecular Genetics·S AkiyamaM M Gottesman
Oct 1, 1994·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W J JansenE Boven
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H L McLeod
Apr 1, 1994·Leukemia Research·K Nooter, P Sonneveld

❮ Previous
Next ❯

Citations

Oct 6, 1997·Pathology International·T KakiharaI Emura
Nov 13, 2010·Journal of Cellular and Molecular Medicine·Dan-Dan FengYue-Qin Chen
Feb 27, 2003·The Journal of Pharmacology and Experimental Therapeutics·Shuzhong Zhang, Marilyn E Morris

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.